The 6th China Bio-pharmaceutical Innovation and Cooperation Conference & 2022 China Bio-pharmaceutical Industry Value List Awards Ceremony was successfully held recently, at which Cygnus Bio was honored on the “2022 China Bio-pharmaceutical Industry Value List” and recognized as a “Most Promising Biotechnology Enterprise”.
On August 4–5, 2022, the “6th China Bio-pharmaceutical Innovation and Cooperation Conference 2022 & 2022 China Bio-pharmaceutical Industry Value List Awards Ceremony” was grandly held in Suzhou, co-hosted by Welcome Medical and the Beijing Medical Reward Foundation.
Backed by its top-tier R&D talent, outstanding innovation capabilities and advantages in multiple core technologies, Cygnus Bio was selected by the judging panel through professional evaluation and successfully named among the “Most Promising Biotechnology Enterprises”.
This year’s bio-pharmaceutical conference focused on cutting-edge technological updates, interpreted the latest industrial policies, and built a multi-stakeholder platform connecting industry, academia, research and capital. jointly launched by Welcome Medical and the Hwayi Research Institute, the “2022 China Bio-pharmaceutical Industry Value List” was compiled through comprehensive assessment from multiple dimensions including strategy, product portfolio, competitiveness, team strength, commercialization potential and value orientation, as well as in-depth evaluation of sectors, industries and enterprises. The final list was determined through a rigorous process of nomination collection, data verification and systematic research.
The list features nine categories of awards, covering small-molecule innovative drugs, antibody innovative drugs, biotechnology, CXO, innovative therapies, service providers, industrial parks, investment institutions and boutique investment banks, selected from candidate enterprises in corresponding sub-sectors. Among them, the biotechnology industry as a whole maintains strong growth momentum and is poised to become a 100-billion-level market in the future.
The release of the “2022 China Bio-pharmaceutical Industry Value List” comprehensively showcases the innovation awareness, achievements and capabilities of a group of outstanding bio-pharmaceutical enterprises. It encourages enterprises to address shortcomings, strengthen advantages and explore new development paths, with a focus on tackling key difficulties and bottlenecks across the entire industrial chain, thus unlocking greater possibilities for the translation of scientific and technological achievements.
